Randomized trial demonstrates cognitive and functional benefits with donepezil over 12 months in moderate-to-severe Alzheimer's disease, highlighting the value of continued therapy.
In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).
No takes yet. Share an insight, caveat, or question.
Howard et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: